Capsulution NanoScience AG Fully automatic production of nanocapsules filled with selected active substancesBerlin (30th September, 2002) - Capsulution has reached another important milestone in its corporate development by putting into operation a new computer-controlled production plant. The new "encapsulation-plant" allows the fully automatic production of capsules filled with selected active substances based on Capsulution's patented LBL-Technology®, the unique encapsulation method developed by a group of scientists at the Max-Planck-Institute of Colloids and Interfaces in Golm, many of whom are among the founders of the company.
The new plant is currently being used in a co-operation project with a globally operating pharmaceutical corporation starting September 2002 to produce larger quantities of test samples. Dr. Jörg Mayer, process engineer and head of Capsulution.s up-scaling unit is very pleased: "With the putting into operation of our new production mini-plant, we are able to provide confirmation for the deployment of our LBL-Technology® under industrial conditions. We are furthermore in the position to demonstrate that we are able to fulfil the requirements for a validated production as demanded by the pharmaceutical industry."
The CFO, Alexander Hermann adds: "The establishment of our encapsulation technology using our plant is of prime importance in measuring the costs of the production process. As a result we already know that the costs for the production of our drug-delivery systems are competitive."
About Capsulution NanoScience AG:
Capsulution NanoScience develops innovative drug-delivery systems for the convenient, efficient and safe delivery of pharmaceutical substances. The term "LBL" (derived from "layer-by-layer") refers to the unique encapsulation method developed by a group of scientists at the Max-Planck-Institute of Colloids and Interfaces in Golm, near Potsdam, Germany, many of whom are among the founders of the company. The walls of the nano- and micro-capsules are built up layer-wise and, based on their minute size, their functionality and their highly reproducible production process can be used for a multitude of different applications. Accordingly, the precisely sized capsules (ranging from 100 nm to 10 µm) can be adapted to the intended application and be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer. The capsules can also be applied in cosmetics, in diagnostics and for crop protection. Today, the Berlin-based company has 17 employees. In 2001 Capsulution successfully completed its first round of financing, raising approximately 3 million Euro. Investors include venture-capital companies such as the Berlin Seed Capital Fund (BSCF) and the Kapitalbeteiligungsgesellschaft des Landes Brandenburg (KBB) as well as the Technologiebeteiligungsgesellschaft der Deutschen Ausgleichsbank (tbg). Capsulution has already entered into several co-operation agreements with industrial corporations, including one with Bayer AG in December 2001.
Contact:
Capsulution NanoScience AG
Alexander Herrmann (CFO)
Volmerstr. 7b
D- 12489 Berlin, Germany
Tel.: +49-(0)30-63923627
Fax.: +49-(0)30-63923601
Web: www.capsulution.com
eMail: alexander.herrmann@capsulution.com
© BIOCOMMUNICATIONS.net GmbH, Brunnenstr. 128, D- 13355 Berlin/Germany - Reprint free of charge, please supply copy
